Oligometastatic or oligoprogressive ovarian, fallopian tube or primary peritoneal carcinoma research hub

SOPRANO - Stereotactic radiotherapy alone or stereotactic radiotherapy follow by niraparib treatment for ovarian cancer with progressive disease in three or less lesions, or recurrence of 3 or less metastatic lesions that had previously achieved complete response.

This trial tests whether targeted, pinpoint radiotherapy can help control ovarian cancer that has grown in just a few small spots after drug treatment. Patients receive radiotherapy to the growing tumours, either on its own or followed by a daily targeted tablet called niraparib, to delay further cancer progression.